Company Description
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.
The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals.
The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson’s disease, and endocrine disorders.
This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson’s disease.
The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs.
This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers.
It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies.
The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018.
Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
| Country | United States |
| Founded | 2002 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 8,300 |
| CEO | Chirag K. Patel |
Contact Details
Address: 400 Crossing Boulevard, 3rd Floor Bridgewater, New Jersey 08807 United States | |
| Phone | 908 947 3120 |
| Website | amneal.com |
Stock Details
| Ticker Symbol | AMRX |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001723128 |
| CUSIP Number | 03168L105 |
| ISIN Number | US03168L1052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chintu Patel R.Ph. | Co-Founder, Co-Chief Executive Officer and Director |
| Chirag K. Patel | Co-Founder, Co-Chief Executive Officer, President and Director |
| Anastasios G. Konidaris | Executive Vice President and Chief Financial Officer |
| Jason B. Daly Esq. | Executive Vice President, Chief Legal Officer and Corporate Secretary |
| Nikita Shah | Executive Vice President and Chief Human Resources Officer |
| Andrew S. Boyer | Executive Vice President and Chief Commercial Officer of Generics and Biosciences |
| Anthony DiMeo | Head of Investor Relations |
| Gregory Sgammato | Senior Vice President of Corporate Development |
| Pranav Mehta | Senior Vice President of Strategic Sourcing and Supply Management |
| Dr. Sanjay Kumar Jain Ph.D. | Chief Quality Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 17, 2025 | SCHEDULE 13D/A | Filing |
| Mar 14, 2025 | 144 | Filing |
| Mar 6, 2025 | 8-K | Current Report |
| Mar 5, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Feb 28, 2025 | 10-K | Annual Report |